OptiNose Inc
NASDAQ:OPTN
OptiNose Inc
Inventory
OptiNose Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OptiNose Inc
NASDAQ:OPTN
|
Inventory
$11.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$11.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$12.2B
|
CAGR 3-Years
41%
|
CAGR 5-Years
25%
|
CAGR 10-Years
13%
|
|
OptiNose Inc
Glance View
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.
See Also
What is OptiNose Inc's Inventory?
Inventory
11.5m
USD
Based on the financial report for Dec 31, 2024, OptiNose Inc's Inventory amounts to 11.5m USD.
What is OptiNose Inc's Inventory growth rate?
Inventory CAGR 5Y
27%
Over the last year, the Inventory growth was 42%. The average annual Inventory growth rates for OptiNose Inc have been -1% over the past three years , 27% over the past five years .
